Characterization of hepatocellular carcinoma cell lines based on cell adhesion molecules

International Journal of Molecular Medicine

Volumn 29, Issue 6, 2012, Pages 1158-1164

  Jung, Cheol Woong ^a   Song, Tae Jin ^b   Lee, Kun Ok ^b   Choi, Sae Byeol ^a   Kim, Wan Bae ^a   Suh, Sung Ock ^c   Kim, Young Chul ^c   Choi, Sang Yong ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

Author keywords

Cell adhesion molecules; Hepatocellular carcinoma; Molecular targeted therapy

Indexed keywords

ALPHA3 INTEGRIN; ALPHA5 INTEGRIN; BETA2 INTEGRIN; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SUBUNIT; REAL TIME POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CELL LINE, TUMOR; E-SELECTIN; HUMANS; INTEGRINS; INTERCELLULAR ADHESION MOLECULE-1; LIVER NEOPLASMS; MALE; PROTEIN SUBUNITS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84860522973     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.951     Document Type: Article

References (57)

1. Bruix J and Sherman M: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005. (Pubitemid 43112690)
2. Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442, 2003. (Pubitemid 36152543)
3. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007. (Pubitemid 46890874)
4. Bruix J and Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35: 519-524, 2002. (Pubitemid 34183954)
5. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981. (Pubitemid 11167383)
6. Therasse P, Arbuck S, Eisenhauer E, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
7. Leung TW, Patt YZ, Lau WY, et al: Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5: 1676-1681, 1999. (Pubitemid 29334445)
8. Lau WY, Leung TW, Lai BS, et al: Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 233: 236-241, 2001. (Pubitemid 32106078)
9. Llovet JM, Ricci S and Mazzaferro V: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 24: 378-390, 2008.
10. Makrilia N, Kollias A, Manolopoulos L, et al: Cell adhesion molecule: role and clinical significance in cander. Cancer Invest 27: 1023-1037, 2009.
11. Jiang WG, Puntis MC and Hallett MB: Molecular and cellular basis of cancer invasion and metastasis: implication for treatment. Br J Surg 81: 1576-1590, 1994. (Pubitemid 24349926)
12. Llovet JM and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327, 2008.
13. Park JG, Lee JH, Kang MS, et al: Characterization of cell lines established from human hepatocellualar carcinoma. Int J Cancer 62: 276-282, 1995
14. Lee JH, KU JL, Park YJ, et al: Establishment and characterization of four human hepatocellular carcinoma cell lines containing hepatitis B virus DNA. World J Gastroenterol 5: 289-295, 1999.
15. Knowles BB, Howe CC and Aden DP: Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209: 497-499, 1980.
16. Song TJ, Eisenberg DP, Fong Y, et al: Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines. J Gastrointest Surg 10: 532-542, 2006. (Pubitemid 43619155)
17. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al: Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 31: 302-308, 2000.
18. Okumoto K, Hattori E, Tamura K, et al: Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int 24: 21-28, 2004. (Pubitemid 38351210)
19. Zhou L, Liu J and Luo F: Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 12: 1175-1181, 2006.
20. Banks RE, Gearing AJ, Hemingway IK, et al: Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer 68: 122-124, 1993. (Pubitemid 23178563)
21. Ye C, Kiriyama K, Mistuoka C, et al: Expression of E-selectin on endothelial cells of small veins in human colorectal cancer. Int J Cancer 61: 455-460, 1995.
22. Zhang BH, Chen H, Yao XP, et al: E-selectin and its ligand-sLeX in the metastasis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 1: 80-82, 2002. (Pubitemid 36748174)
23. van de Stolpe A and van der Saag PT: Intercellular adhesion molecule-1 (Review). J Mol Med 74: 13-33, 1996.
24. Shimizu Y, Minemura M, Tsukishiro T, et al: Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis. Hepatology 22: 525-531, 1995.
25. Sun JJ, Zhou XD, Liu YK, et al: Invasion and metastasis of liver cancer: expression of intercellular adhesion molecule 1. J Cancer Res Clin Oncol 125: 28-34, 1999. (Pubitemid 29062333)
26. Stupack DG: The biology of integrins. Oncology (Williston Park) 21 (Suppl 3): S6-S12, 2007.
27. Luo BH, Carman CV and Springer TA: Structural basis of integrin regulation and signaling. Annu Rev Immunol 25: 619-647, 2007. (Pubitemid 46697919)
28. Giancotti FG and Ruoslahti E: Integrin signaling. Science 285: 1028-1032, 1999.
29. Stupack DG and Cheresh DA: Get a ligand, get a life, integrins, signaling, and cell survival. J Cell Sci 115: 3729-3738, 2002. (Pubitemid 35203599)
30. Yang C, Zeisberg M, Lively JC, et al: Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res 63: 8312-8317, 2003. (Pubitemid 37549483)
31. Giannelli G, Bergamini C, Fransvea E, et al: Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Lab Invest 81: 613-627, 2001. (Pubitemid 32298807)
32. Hu PP, Datto MB and Wang XF: Molecular mechanisms of transforming growth factor-beta signal. Endocr Rev 24: 1128-1136, 1998.
33. Oft M, Heider KH and Berg H: TGF-beta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8: 1243-1252, 1998. (Pubitemid 28540052)
34. Giannelli G, Fransvea E, Marinosci F, et al: Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 161: 183-193, 2002. (Pubitemid 34760784)
35. Katabami K, Mizuno H, Sano R, et al: TGF-β1 upregulates transcription of α3 integrin gene in heptocellular carcinoma cells via Ets-transcription factor-binding motif in the promoter region. Clin Exp Metastasis 22: 539-548, 2005. (Pubitemid 43234638)
36. Xu Z, Shen MX, Ma DZ, et al: TGF-β1 promoted epithelial-to- mesenchymal transformation and cell adhesion contribute to TGF-β1 enhanced cell migration in SMMC-7721 cells. Cell Res 13: 343-350, 2003. (Pubitemid 43231850)
37. Schlitt HJ, Neipp M, Weimann A, et al: Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol 17: 324-331, 1999. (Pubitemid 29022410)
38. Song GW, Hwang S and Lee SG: Liver transplantation in patients with hepatocellular carcinoma. Korean J Gastroenterol 55: 350-360, 2010 (In Korean).
39. Syrigos KN and Karayiannakis AJ: Adhesion molecules as targets for the treatment of neoplastic diseases. Curr Pharm Des 12: 2849-2861, 2006. (Pubitemid 44184640)
40. Villanueva A, Newell P, Chiang D, et al: Genes and signaling pathways involved in the pathogenesis of HCC. Senin Liver Dis 27: 55-76, 2007.
41. Huynh H, Nguyen TT, Chow KH, et al: Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 3: 19, 2003.
42. Gollob JA, Wilhelm S, Carter C, et al: Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 33: 392-406, 2006. (Pubitemid 44142735)
43. Siegel AB, Cohen EI, Ocean A, et al: Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26: 2992-2998, 2008.
44. Hsu CH, Yang TS, Hsu C, Toh HC, et al: Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 102: 981-986, 2010.
45. Vestweber D and Blanks JE: Mechanisms that regulate the function of the selectins and their lignads. Physiol Rev 79: 181-213, 1999. (Pubitemid 29056952)
46. Bird MI, Foster MR, Priest R, et al: Selectins: physiological and pathophysiological roles. Biochem Soc Trans 25: 1199-1206, 1997. (Pubitemid 27528562)
47. Koch AE, Halloran MM, Haskell CJ, et al: Angiogensis is medicated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376: 517-519, 1995.
48. Collins T, Read MA, Neish AS, et al: Trascriptional regulation of endothelial cell adhesion molecules: NF-kappaB and cytokine-inducible enhancers. FASEB J 9: 899-909, 1995.
49. Khatib AM, Fallavollita L, Wancewicz EV, et al: Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. Cancer Res 62: 5393-5398, 2002.
50. Gout S, Tremblay PL and Huot J: Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis. Clin Exp Metastasis 25: 335-344, 2008. (Pubitemid 351752950)
51. Marlin SD and Springer TA: Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 51: 813-819, 1987.
52. Yang L, Froio RM, Sciuto TE, et al: ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha activated vascular endothelium under flow. Blood 106: 584-592, 2005. (Pubitemid 40981255)
53. Torii A, Harada A, Nakao A, et al: Expression of intercellular adhesion molecule-1 in hepatocellular carcinoma. J Surg Oncol 53: 239-242, 1993. (Pubitemid 23225259)
54. Momosaki S, Yano H, Ogasawara S, et al: Expression of intercellular adhesion molecule 1 in human hepatocellular carcinoma. Hepatology 22: 1708-1713, 1995.
55. Tian J, Tang ZY, Ye SL, et al: New human hepatocellular carcinoma cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer 81: 814-821, 1999. (Pubitemid 29504690)
56. Jaskiewicz K and Chasen MR: Differential expression of transforming growth factor alpha, adhesions molecules and integrins in primary, metastatic liver tumors and in liver cirrhosis. Anticancer Res 15: 559-562, 1995.
57. Yao M, Zhou XD, Zha XL, et al: Expression of the integrin alpha5 subunit and its mediated cell adhesion in hepatocellular carcinoma. J Cancer Res Clin 123: 435-440, 1997. (Pubitemid 27356304)